Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 9 May are set out below…
Pearce IP BioBlast® for the week ending 9 May 2025
read more
Naomi Pearce named finalist in two categories at the 2025 Partner of the Year Awards
Pearce IP’s Founder and CEO Naomi Pearce is a finalist in two categories of the 2025 Lawyers Weekly Partner of the Year Awards: Senior Partner of the Year – 15 Years or More...
Pearce IP BioBlast® for the week ending 2 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 2 May are set out below…
Pearce IP Strengthens New Zealand Team & Welcomes Executive Sally Paterson
Sally Paterson Joins Pearce IP – Executive Lawyer, Patent and Trade Mark Attorney
Two Pearce IP Leaders Ranked in 2025 WIPR Diversity “Top 100” List
Two Pearce IP leaders have been ranked in the WIPR Diversity & Inclusion Top 100 People in IP for 2025. This annual list honours and celebrates the world’s “top 100”...
Pearce IP BioBlast® for the fortnight ending 25 April 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 25 April 2025 are set out below…
Naomi Pearce Ranked in Doyle’s Guide 2025 for IP Litigation
Founder and CEO Naomi Pearce has been recommended in the 2025 NSW Leading Contentious IP Lawyers List in the Doyles Guide for Australia released on 24 April. Doyle’s Guide is an...
Helen Macpherson Ranked in 2026 Best Lawyers in Australia
We are delighted to share that Helen Macpherson, Pearce IP’s Executive Lawyer and Head of Litigation (Australia) has again been ranked in the 2026 edition of The Best Lawyers in...
PiPCast™ | Patent Litigation Procedure – New Zealand vs. Australia
In this PiPCast™, Heads of Litigation, Helen Macpherson and Paul Johns compare patent litigation procedures in Australia and New Zealand.
Pearce IP BioBlast® for the week ending 11 April 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 11 April 2025 are set out below…
Pearce IP New Zealand is Officially Open for Business
It has been a big week at Pearce IP as we gathered our clients, colleagues and New Zealand based team at Auckland’s highest rooftop bar to celebrate the launch of Pearce IP in New Zealand.
Pearce IP BioBlast® for the week ending 4 April 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 4 April 2025 are set out below…
Pearce IP BioBlast® for the week ending 28 March 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 28 March 2025 are set out below…
Pearce IP BioBlast® for the week ending 21 March 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 21 March 2025 are set out below…
Pearce IP BioBlast® for the week ending 14 March 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 14 March 2025 are set out below…
The End of the Road: High Court refuses Bayer’s Rivaroxaban Patents Special Leave Application
Last year, we reported on Sandoz’ victory in its appeal regarding the validity of two of Bayer’s Australian Xarelto® (rivaroxaban) patents…
Pearce IP BioBlast® for the week ending 7 March 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 March 2025 are set out below:
Opposition Succeeds as Claimed Polymorph No Different to Prior Art, Based On ‘Gold Standard’ Comparison
In October 2024, Delegate C. Mitchell of the Australian Patent Office upheld a decision to reject AFT Pharmaceuticals’ (AFT) drug combination patent applications – AU2022201576 (’576) and its divisional child
Pearce IP BioBlast® for the week ending 28 February 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 28 February 2025 are set out below:
The Right Dose: Opposition to Janssen’s Dosing Regimen Patent Amendments Denied
In a split 3:2 decision, Gordon A-CJ, Edelman and Steward JJ of the High Court (the Majority) has dismissed the Commonwealth’s appeal in which the Commonwealth sought to overturn the decision of Justice Nicholas
Pearce IP BioBlast® for the week ending 21 February 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 21 February 2025 are set out below:
Pearce IP BioBlast® for the week ending 14 February 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 February 2025 are set out below:
Cold Comfort: AFT’s Cold and Flu Combination Medicine Patent Applications Found Obvious
In October 2024, Delegate C. Mitchell of the Australian Patent Office upheld a decision to reject AFT Pharmaceuticals’ (AFT) drug combination patent applications – AU2022201576 (’576) and its divisional child
Pearce IP BioBlast® for the week ending 7 February 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 February 2025 are set out below:
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.